Please login to the form below

Not currently logged in
Email:
Password:

Transcept resubmits sleep drug

Transcept Pharmaceuticals has resubmitted the US new drug application for Intermezzo, potentially the first drug cleared in the US specifically for a certain type of insomnia

Transcept Pharmaceuticals has resubmitted the US new drug application for Intermezzo (zolpidem tartrate), a treatment of insomnia characterised by difficulty returning to sleep after middle of the night awakening. If approved, the sublingual tablet will be the first drug cleared in the US specifically for that usage and will be marketed by Purdue Pharma.

The resubmission responds to issues raised in a complete response letter issued by the US Food and Drug Administration (FDA) in late 2009. If the resubmission is accepted as complete by the FDA, Transcept anticipates a six-month review for the drug.

The new application package includes data from a highway driving study and redesigned product packaging and instructional tools, as well as other new information.  The resubmitted application also includes a recent epidemiology study showing that sleep aids approved for bedtime dosing are frequently used by consumers in the middle of the night although they are not cleared for that use.

"We plan to work closely with the FDA through the resubmission process and are fully committed to making this important therapeutic option available to insomnia patients," Transcept CEO Glenn A Oclassen said in a statement.

Purdue licensed US rights to Intermezzo through an August 2009 deal that could be worth up to $145m to Transcept if certain milestones are met. The drug is a low-dose version of sanofi-aventis' Ambien.

18th January 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Four Health Communications

Formerly known as Packer Forbes Communications, Four Health Communications is an award-winning, integrated healthcare communications agency for pharma, biotech, NGOs...

Latest intelligence

Empowered patients: shaking the foundations of healthcare
Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....

Infographics